Clinical trials
Phase 3 Carcinoma, Non-Small-Cell Lung trials in South Korea
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
197 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 2 |
| 2005 | 6 |
| 2006 | 7 |
| 2007 | 5 |
| 2008 | 11 |
| 2009 | 7 |
| 2010 | 4 |
| 2011 | 3 |
| 2012 | 4 |
| 2013 | 4 |
| 2014 | 6 |
| 2015 | 12 |
| 2016 | 7 |
| 2017 | 6 |
| 2018 | 13 |
| 2019 | 10 |
| 2020 | 16 |
| 2021 | 9 |
| 2022 | 14 |
| 2023 | 12 |
| 2024 | 16 |
| 2025 | 13 |
| 2026 | 8 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 79 |
| Active, not recruiting | 50 |
| Recruiting | 34 |
| Terminated | 26 |
| Unknown status | 7 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 26 |
| Merck Sharp & Dohme LLC | 25 |
| Hoffmann-La Roche | 21 |
| Eli Lilly and Company | 13 |
| Bristol-Myers Squibb | 12 |
| Pfizer | 12 |
| Novartis Pharmaceuticals | 10 |
| Boehringer Ingelheim | 9 |
| Samsung Medical Center | 6 |
| Daiichi Sankyo | 4 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Non-Small-Cell Lung | 197 |
| Lung Neoplasms | 33 |
| Carcinoma | 12 |
| Neoplasm Metastasis | 10 |
| Neoplasms | 8 |
| Adenocarcinoma | 5 |
| Lung Diseases | 5 |
| Carcinoma, Large Cell | 4 |
| Carcinoma, Squamous Cell | 4 |
| Adenocarcinoma of Lung | 3 |
Trials
Showing 1 to 25 of 197. Each trial links to its page on Pharma Observatory.
97 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.